Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis.
作者信息
Hodsman Anthony, Papaioannou Alexandra
机构信息
Division of Nephrology, University of Western Ontario and St. Joseph's Health Centre, London, Ont.
出版信息
CMAJ. 2006 Jul 4;175(1):48. doi: 10.1503/cmaj.060624.
Abstract
摘要
相似文献
1
Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis.
CMAJ. 2006 Jul 4;175(1):48. doi: 10.1503/cmaj.060624.
2
Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window.
Curr Osteoporos Rep. 2008 Mar;6(1):24-30. doi: 10.1007/s11914-008-0005-9.
3
Safety of parathyroid hormone for the treatment of osteoporosis.
Curr Osteoporos Rep. 2008 Mar;6(1):12-6. doi: 10.1007/s11914-008-0003-y.
4
Treatment of osteoporosis with parathyroid hormone and teriparatide.
Calcif Tissue Int. 2009 Mar;84(3):159-70. doi: 10.1007/s00223-009-9218-x. Epub 2009 Feb 3.
5
Parathyroid hormone analogues in the therapy of osteoporosis.
Wien Klin Wochenschr. 2008;120(11-12):321-4. doi: 10.1007/s00508-008-0999-0.
6
The use of PTH in the treatment of osteoporosis.
Arq Bras Endocrinol Metabol. 2010 Mar;54(2):213-9. doi: 10.1590/s0004-27302010000200018.
7
[PTH analogues: comparable or different?].
Tijdschr Gerontol Geriatr. 2008 Oct;39(5):176-81. doi: 10.1007/BF03078151.
8
The use of parathyroid hormone in the treatment of osteoporosis.
Rev Endocr Metab Disord. 2006 Jun;7(1-2):113-21. doi: 10.1007/s11154-006-9007-z.
9
Biologicals in osteoporosis: teriparatide and parathyroid hormone in women and men.
Curr Osteoporos Rep. 2010 Sep;8(3):154-61. doi: 10.1007/s11914-010-0024-1.
10
Anabolic skeletal therapy for osteoporosis.
Arq Bras Endocrinol Metabol. 2006 Aug;50(4):745-54. doi: 10.1590/s0004-27302006000400019.
引用本文的文献
1
The Effect of Omega-9 on Bone Viscoelasticity and Strength in an Ovariectomized Diet-Fed Murine Model.
Nutrients. 2023 Feb 28;15(5):1209. doi: 10.3390/nu15051209.
2
Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic Review.
Iran J Public Health. 2022 Jul;51(7):1502-1512. doi: 10.18502/ijph.v51i7.10084.
3
The Effects of Selenium on Bone Health: From Element to Therapeutics.
Molecules. 2022 Jan 8;27(2):392. doi: 10.3390/molecules27020392.
4
Economic burden of osteoporosis in the world: A systematic review.
Med J Islam Repub Iran. 2020 Nov 12;34:154. doi: 10.34171/mjiri.34.154. eCollection 2020.
5
Bisphosphonates and parathyroid hormone analogs for improving bone quality in spinal fusion: State of evidence.
Orthop Rev (Pavia). 2020 Aug 18;12(2):8590. doi: 10.4081/or.2020.8590. eCollection 2020 Aug 6.
6
Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture.
Osteoporos Int. 2016 Mar;27(3):963-969. doi: 10.1007/s00198-015-3378-5. Epub 2015 Oct 30.
7
Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products.
Nutr Res Rev. 2014 Dec;27(2):252-67. doi: 10.1017/S0954422414000183. Epub 2014 Nov 14.
8
Osteoanabolics.
Indian J Endocrinol Metab. 2012 May;16(3):349-57. doi: 10.4103/2230-8210.95662.
9
Antiosteoporotic Activity of Dioscorea alata L. cv. Phyto through Driving Mesenchymal Stem Cells Differentiation for Bone Formation.
Evid Based Complement Alternat Med. 2011;2011:712892. doi: 10.1155/2011/712892. Epub 2011 Jun 29.
10
Parathyroid hormone analogues in the treatment of osteoporosis.
Nat Rev Endocrinol. 2011 Jul 12;7(11):647-56. doi: 10.1038/nrendo.2011.108.
本文引用的文献
1
Parathyroid hormone for the treatment of osteoporosis: a systematic review.
CMAJ. 2006 Jul 4;175(1):52-9. doi: 10.1503/cmaj.050929.
2
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.
Endocr Rev. 2005 Aug;26(5):688-703. doi: 10.1210/er.2004-0006. Epub 2005 Mar 15.
3
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.
CMAJ. 2002 Nov 12;167(10 Suppl):S1-34.
4
Odds ratio, relative risk, absolute risk reduction, and the number needed to treat--which of these should we use?
Value Health. 2002 Sep-Oct;5(5):431-6. doi: 10.1046/J.1524-4733.2002.55150.x.
5
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
N Engl J Med. 2001 May 10;344(19):1434-41. doi: 10.1056/NEJM200105103441904.
6
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
Osteoporos Int. 2000;11(1):83-91. doi: 10.1007/s001980050010.
7
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
JAMA. 1999 Oct 13;282(14):1344-52. doi: 10.1001/jama.282.14.1344.
8
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Lancet. 1996 Dec 7;348(9041):1535-41. doi: 10.1016/s0140-6736(96)07088-2.
Zotero 插件